FDA OKs Alexion Soliris in rare autoimmune brain, spinal cord disorder

The FDA approves Alexion Pharmaceuticals’ (ALXN +0.9%) Soliris (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who express an antibody called anti-aquaporin-4 (AQP4) (a biomarker for confirming the diagnosis).

NMOSD is a rare autoimmune disorder of the brain and spinal cord characterized by inflammation of the spinal cord (myelitis) and optic nerve (optic neuritis). It occurs in 1-10 per 100,000 individuals worldwide.

https://seekingalpha.com/news/3474379-fda-oks-alexions-soliris-rare-autoimmune-disorder-brain-spinal-cord